BioSpace News Archive

Nolato AB has published its interim report for the third quarter of 2019.

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, presented additional new data from Cohort 1 of its ongoing Phase 2/3 randomized, double-blind, placebo-controlled clinical study (iNO-PF) of INOpulse® for the treatment of Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) as a late-breaking oral presentation at the American College of Chest Physicians (CHEST) 2019 Annual Meeting in New Orleans.

China Jo-Jo Drugstores, Inc. announced that the Company hosted a reception for Mr. Jiangyong Zhou, Member of the Standing Committee of Zhejiang Provincial Party Committee and Secretary of Hangzhou Municipal Party Committee, during the National 21st Electric Expo and National 4th Leisure Expo at Hangzhou International Expo Center on October 19th, 2019

Maze Therapeutics, a company focused on translating genetic insights into new medicines, announced that Jonathan Lim, M.D., founder and managing partner at City Hill Ventures, has joined the company’s board of directors.

Repro Med Systems, Inc. announced a new dba name, KORU Medical Systems, which the Company will begin using in place of RMS Medical Products on October 24, 2019.

BlackThorn Therapeutics, Inc., announced that the company presented new data science research into the underlying biology of neurobehavioral disorders at the 49th annual meeting of the Society for Neuroscience taking place October 19-23 in Chicago.

This coming Saturday, Oct. 26, 2019, from 10 AM to 2 PM, the U.S. Drug Enforcement Administration (DEA) will host its 18th National Drug Take Back Day in nine years.

CVS Health Corporation will hold a conference call with analysts and investors on Wednesday, November 6, 2019, at 8:00 a.m. to discuss its financial results for the third quarter of 2019.

Magnesium is the fourth most abundant mineral in the body, spearheading more than 300 biochemical reactions, yet as many as 90% of people are deficient, a nationally regarded doctor tells the Epsom Salt Council.

Building on its success in leading pragmatic approaches for clinical study design, the Duke Clinical Research Institute (DCRI), part of the Duke University School of Medicine, has been awarded funding to conduct a pragmatic trial studying the effectiveness of statins in older adults without known cardiovascular disease